133
Participants
Start Date
July 15, 2025
Primary Completion Date
March 15, 2028
Study Completion Date
July 15, 2028
Tepotinib
Tepotinib will be given orally once daily at the dose of 500mg of tepotinib hydrochloride hydrate.
Pemetrexed (Alimta)
500 mg/m² every 3 weeks
Vinorelbine
25-30 mg/m² D1, D8, every 3 weeks
Gemcitabine alone
1250 mg/m² D1, D8, every 3 weeks
Docetaxel
75 mg/m² every 3 weeks
Paclitaxel
90 mg/m² D1, D8, D15 every 4 weeks If bevacizumab added: 10 mg/kg D1, D15 every 4 weeks
Pembrolizumab
200 mg every 3 weeks
Nivolumab
240 mg every 2 weeks
Atezolizumab
1200 mg every 3 weeks
Dijon - Centre Georges-François Leclerc, Dijon
Institut de Cancérologie de l'Ouest - René Gauducheau, Saint-Herblain
Nancy - CHU, Vandœuvre-lès-Nancy
Strasbourg - NHC, Strasbourg
Centre Hospitalier Général - Pau, Pau
Centre Léon Bérard, Lyon
AP-HP Hôpital Cochin, Paris
AP-HP Hôpital Tenon, Paris
Toulon - CHI, Toulon
Sens - CH, Sens
Centre Hospitalier Intercommunal de Créteil, Créteil
Besançon - CHU, Besançon
Bordeaux - Institut Bergonie, Bordeaux
Brest - CHU, Brest
Caen - CRLCC, Caen
Grenoble - CHU, Grenoble
CHD Vendée, La Roche-sur-Yon
Le Mans - CHG, Le Mans
CHRU de Lille, Lille
Institut Paoli Calmette, Marseille
Marseille - APHM, Marseille
Montpellier - CHU, Montpellier
Centre Antoine Lacassagne, Nice
Paris - APHP Bichat, Paris
Bordeaux - CHU, Pessac
CHU Toulouse, Toulouse
CHRU de Tours, Tours
CH de Valence, Valence
Gustave Roussy, Villejuif
Intergroupe Francophone de Cancerologie Thoracique
OTHER